CORTCorcept Therapeutics Incorporated
$121.12+50% 1Y
$121.12
$32.1552 weeks$123.53
CORT in its own filings
CORT's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
424
Events found in the filings · across 2,043 filings · the record starts in 2004
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 23, 2026
Most recent filing · Form 8-K
- Record starts
- May 28, 2004
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Delisting notice / listing-rule failure3 occurrences
- 2007-04-05
- SEC comment-letter activity39 occurrences
- 2025-12-11
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.Director or officer change · Form 8-K
- Jul 29, 2026Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 17, 2026On June 17, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome.Other event · Form 8-K
- Jun 3, 2026On May 19, 2026, Corcept Therapeutics Incorporated (the “Company”) learned that the United States Department of Justice (the “DOJ”) had filed a Notice of Election to Decline Intervention (the “Notice”) in a civil qui tam action filed against the company, captioned U.S. et al. ex rel.Other event · Form 8-K
- May 28, 2026On May 21, 2026, Corcept Therapeutics Incorporated (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
- Apr 30, 2026Corcept Therapeutics Announces First Quarter Financial Results.Earnings release · press release
- Mar 25, 2026On March 25, 2026, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved Lifyorli ™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal …Other event · Form 8-K
- Feb 19, 2026On February 19, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym ® does not infringe two of the Company’s patents concerning methods of …Other event · Form 8-K
- Jan 22, 2026On January 22, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that ROSELLA, the Company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint.Other event · Form 8-K
- Dec 31, 2025On December 31, 2025, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…